Century Therapeutics Inc
Company Profile
Business description
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Contact
25 N 38th Street
11th Floor
PhiladelphiaPA19104
USAT: +1 267 817-5790
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
165
Stocks News & Analysis
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
stocks
These 2 ASX stocks look materially overvalued after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,804.20 | 4.60 | 0.05% |
| CAC 40 | 8,150.14 | 107.95 | 1.34% |
| DAX 40 | 22,476.03 | 328.00 | 1.48% |
| Dow JONES (US) | 44,379.16 | 10.60 | 0.02% |
| FTSE 100 | 8,745.72 | 61.72 | -0.70% |
| HKSE | 21,814.37 | 43.55 | -0.20% |
| NASDAQ | 19,681.96 | 32.01 | 0.16% |
| Nikkei 225 | 39,461.47 | 497.77 | 1.28% |
| NZX 50 Index | 12,905.98 | 7.97 | -0.06% |
| S&P 500 | 6,051.84 | 0.13 | -0.00% |
| S&P/ASX 200 | 8,540.00 | 4.70 | 0.06% |
| SSE Composite Index | 3,332.48 | 13.90 | -0.42% |